WGI-0301

DRUG3 trials

Sponsors

Zhejiang Haichang Biotech Co., Ltd.

Conditions

Advanced Hepatocellular Carcinoma (HCC)Advanced Solid TumorsHepato Cellular Carcinoma (HCC)Renal Cell Cancer

Phase 1

A Phase I First in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WGI-0301 in Patients With Advanced Solid Tumors

Zhejiang Haichang Biotech Co., Ltd.Advanced Solid Tumors

Start: 2022-08-01End: 2024-12-31Target: 24Updated: 2023-09-26

A Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCC

Not yet recruitingNCT07540832

Zhejiang Haichang Biotech Co., Ltd.Advanced Hepatocellular Carcinoma (HCC)

Start: 2026-09-01End: 2028-10-01Target: 80Updated: 2026-09-15

Phase 2

Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC

Not yet recruitingNCT07494435

Zhejiang Haichang Biotech Co., Ltd.Hepato Cellular Carcinoma (HCC), Renal Cell Cancer

Start: 2026-06-01End: 2028-09-01Target: 230Updated: 2026-03-27